Anywhere in The TriangleClear the filters
Medical research stories in The Triangle
Newest first.
Arrow keys move through them
medical researchFDA Launches Rare Disease Framework Initiative: What It Could Mean for Our Community Highlights
A Cure In Sight
Oct 18 · Raleigh
medical researchThe Inaugural V Foundation for Cancer Research Capital Epicurean Raises Over $720,000 for Cancer Research
V Foundation
Oct 14 · Cary
medical researchCan a Biopsy Help Predict Who Responds to TIL Therapy?
A Cure In Sight
Oct 14 · Raleigh
medical researchWhy Uveal Melanoma Is Different, and What That Means for Treatment
A Cure In Sight
Oct 9 · Raleigh
medical researchA Cure In Sight and UT Southwestern Bring the Ocular Melanoma Community Together at Eye Believe in Dallas
A Cure In Sight
Oct 8 · Raleigh
medical researchDr. Aden Mendoza Receives 2026 Neil Peart Neurosurgery Research Award - Glioblastoma Treatment & Research
Glioblastoma Foundation
Sep 30 · Durham
medical researchAlonzo Mourning Announced as Stuart Scott IMPACT Honoree at 6th Annual V Foundation for Cancer Research Boo-Yah
V Foundation
Sep 25 · Cary
medical researchThe 3rd Annual V Foundation for Cancer Research Chicago Epicurean Raises $1 Million
V Foundation
Sep 22 · Cary
The V Foundation for Cancer Research Announces 2026 Dick Vitale Pediatric Cancer Research Fund Grantees
V Foundation
Sep 8 · Cary
medical researchNew Clues on Why TIL Immunotherapy Works for Some Melanoma Patients
A Cure In Sight
Aug 20 · Raleigh
The V Foundation for Cancer Research Eclipses the $500 Million Milestone in Grant Award Funding
V Foundation
Aug 18 · Cary
medical researchAdvances in Ocular Oncology Offer New Hope for Patients and Families
A Cure In Sight
Aug 16 · Raleigh
medical researchNew Targeted Therapy Shows Early Promise for Metastatic Uveal Melanoma
A Cure In Sight
Aug 12 · Raleigh
medical researchNew Immunotherapy Research May Help Strengthen Future Cancer Treatments
A Cure In Sight
Aug 8 · Raleigh
medical research28th Annual V Foundation for Cancer Research Wine Celebration Raises Nearly $7 Million to Accelerate Breakthrough Cancer Research
V Foundation
Aug 3 · Cary
medical researchNew Research May Improve How Doctors Predict Metastasis Risk in Uveal Melanoma
A Cure In Sight
Aug 3 · Raleigh
A Cure In Sight Earns Charity Navigator’s 2026 Four-Star Rating
A Cure In Sight
Jul 28 · Raleigh
medical researchHope Beyond a Rare Diagnosis: One Father’s Uveal Melanoma Journey Shows the Power of Clinical Trials
A Cure In Sight
Jul 22 · Raleigh
The V Foundation for Cancer Research Announces Recipients for the 2026 Breaking Barriers in Cancer Research Grant Award
V Foundation
Jul 20 · Cary
medical researchNew Blood Test Monitoring Tool Offers Additional Insight for Uveal Melanoma Care
A Cure In Sight
Jul 18 · Raleigh
medical researchGlioblastoma Foundation Marks 10 Years with New Push to Accelerate Personalized Treatment
Glioblastoma Foundation
Jul 14 · Durham
medical researchThe V Foundation for Cancer Research and ESPN Announce Return of Annual ESPYS Week Charity Radio Auction
V Foundation
Jul 7 · Cary
medical researchWNBA Legends Unite Sports, Culture and Community in Support of the V Foundation for Cancer Research
V Foundation
Jun 23 · Cary
medical researchWhy Glioblastoma Treatment is Becoming More Personalized - Glioblastoma Treatment & Research
Glioblastoma Foundation
Apr 8 · Durham
medical researchPhase 1/2a study on Lisavanbulin Published in Journal Cell Reports Medicine - Glioblastoma Treatment & Research
Glioblastoma Foundation
Aug 14 · Durham
medical researchGenomic Testing: Transforming Glioblastoma Therapy - Glioblastoma Treatment & Research
Glioblastoma Foundation
Apr 11 · Durham
medical researchGenomic Testing and 2021 World Health Organization Glioblastoma Classification - Glioblastoma Treatment & Research
Glioblastoma Foundation
Jan 14 · Durham
medical researchGlioblastoma Foundation® Acquires Drug Lisavanbulin - Glioblastoma Treatment & Research
Glioblastoma Foundation
Oct 24 · Durham
FDA Launches Rare Disease Framework Initiative: What It Could Mean for Our Community Highlights
If you’re living with a rare disease, or caring for someone who is, you know how frustrating it can be to wait for treatments that seem to take forever to arrive. That’s why a new announcement from the U.S. Food and Drug Administration caught our attention, and we wanted to share it with our community.
On October 14, 2026, the FDA launched the Rare Disease Framework Initiative, an effort to rethink how treatments for rare diseases are developed and reviewed. As a patient-founded, patient-led community, we were especially glad to see patients placed at the center of this work.
According to the FDA’s white paper, about 30 million Americans, roughly one in ten, live with a rare disease. In the U.S., a disease is considered rare when it affects fewer than 200,000 people, and many affect far fewer. Yet only about 5% of recognized rare diseases have an FDA-approved treatment. The FDA also notes that many patients end up using treatments approved for other conditions because nothing has been proven for their specific disease.
The white paper is honest about the challenges. Patient groups are small and often spread out geographically, which makes clinical trial enrollment slow. Information about how a disease naturally progresses is often limited, and the tools commonly used in larger studies may simply not be available. The FDA says rare diseases need an approach based on the evidence that can realistically be gathered, the type of treatment, and what patients need, and that this approach should be used consistently across its review teams.
4 of 11 paragraphs
World's largest resource for ocular and uveal melanoma information. Find expert insights, support, and the latest research.
A Cure In Sight published this.
Open the story